Oncotarget · 2016 · 44 citations · 33 references
MedicineHematologyOncologyCancer GeneticsHematologic OncologyMolecular OncologyCancer GenomicsCancer PrevalenceHematologic MalignanciesMultiple MyelomaMutation AnalysisNext-generation Sequencing In OncologyCohort Study InvestigationLeukemia PrevalenceLongitudinal Cohort AnalysisMissense MutationsP53 MutationPlasma Cell BiologyPrimary Plasma Cell LeukemiaTp53 Mutations
// Marta Lionetti 1 , Marzia Barbieri 2 , Martina Manzoni 1 , Sonia Fabris 2 , Cecilia Bandini 2 , Katia Todoerti 3 , Filomena Nozza 3 , Davide Rossi 4 , Pellegrino Musto 3 , Luca Baldini 1, 2 , Antonino Neri 1, 2 1 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy 2 Hematology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy 3 Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy 4 Department of Translational Medicine, Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy Correspondence to: Antonino Neri, e-mail: antonino.neri@unimi.it Marta Lionetti, e-mail: marta.lionetti@unimi.it Keywords: multiple myeloma, plasma cell leukemia, TP53 , next-generation sequencing, mutational analysis Received: October 9, 2015     Accepted: January 19, 2016     Published: February 08, 2016 ABSTRACT The prevalence of TP53 mutations greatly varies between tumor types; in multiple myeloma (MM) they were rarely detected at presentation, while increased frequency was reported with disease progression. Using next-generation sequencing, we analyzed TP53 exons 4-9 in a large representative cohort comprising patients with MM at diagnosis and more aggressive forms of plasma cell (PC) dyscrasia, identifying mutations in 4/129 (3%) MM, 6/24 (25%) primary PC leukemia, and 2/10 (20%) secondary PC leukemia cases. A similar increase in prevalence associated with disease aggressiveness (5%, 29.2% and 44%, respectively) was observed for TP53 deletion. Interestingly, in five patients mutations were not concomitant with TP53 deletion. Furthermore, longitudinal analysis revealed the acquisition of TP53 mutations in three of nineteen cases analyzed at relapse. Identified variants were mostly missense mutations concentrated in the DNA binding domain, only partly reflecting the pattern globally observed in human cancers. Our data confirm that TP53 mutations are rare in MM at presentation and rather represent a marker of progression, similarly to del(17p); however, their occurrence even in absence of deletions supports the importance of their assessment in patients with PC dyscrasia, in terms of both risk stratification and therapeutic implications.
33
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr, Petar Stojanov, Scott L. Carter et al. · Cancer Cell · 2014 · 1K citations · Full text
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolò Bolli, Hervé Avet‐Loiseau, David C. Wedge et al. · Nature Communications · 2014 · 906 citations · Full text